Compare Rambus Inc. Common Stock (RMBS) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rambus Inc. Common Stock vs GeneDx Holdings Corp — how do they compare? Rambus Inc. Common Stock trades at $88.61 (market cap $9.99B), while GeneDx Holdings Corp trades at $67.94 (market cap $2.04B). The key difference: Rambus Inc. Common Stock is far larger — about 4.9× GeneDx Holdings Corp's market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, Rambus Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Rambus Inc. Common Stock for 0 Days and GeneDx Holdings Corp for 20 Days on average.
| RMBS | WGS | |
|---|---|---|
Market Cap | $9.99B | $2.04B |
Volume | 1,884,427 | 962,082 |
Sector | Technology | Health |
52-Week High | $170.66 | $167.51 |
52-Week Low | $79.73 | $34.51 |
Typical Hold Time | 0 Days | 20 Days |
Enterprise Value | $9.19B | $2.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Rambus (RMBS) trades at $98.17, down 2.84% over 24 hours, with a neutral technical signal and key support at $96. The company reported strong profitability with a 31.69% net income margin and beat EPS estimates in two of the last three quarters. Recent news highlights its focus on AI infrastructure with new product launches, positioning it to benefit from growing demand for high-speed memory solutions.
The outlook is positive given analyst consensus of a $161.75 price target and 78.57% buy ratings, but risks include high valuation multiples and competitive pressures. Execution on AI-driven growth and maintaining earnings momentum are critical for stock appreciation, while any miss in upcoming results could pressure the premium valuation.
GeneDx Holdings (WGS) trades at $64.96, up 1.79% today, showing mixed technical signals with a bearish moving average trend but bullish oscillators. Fundamentally, the company reported Q2 2026 revenue of $114.4M, beating expectations with a return to adjusted profitability, though full-year 2026 shows a net loss of -$106M. Recent news highlights product launches and CEO recognition, while analyst sentiment remains strongly positive with 91% buy ratings.
The outlook for WGS is cautiously optimistic with strong analyst support and operational improvements, but significant risks persist including negative profitability margins and high valuation multiples. The consensus price target of $81 suggests 25% upside potential, though investors should monitor cash flow trends and competitive pressures in the genomics diagnostics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Rambus Inc. Common Stock
Rambus Inc. is a semiconductor and silicon IP company that licenses chip interface and security technologies, including memory interface chipsets for DDR5 and DDR4 server and client DIMMs, interface IP for PCIe, CXL, and HBM, and security IP such as Root of Trust and memory encryption. It serves data center, AI, automotive, and IoT markets.
Read more on RMBS →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
